Skip to main content

The role of vitamin D in autoimmune diseases: could sex make the difference?


Over the last decades, a central role for vitamin D in immune modulation has been well established. The active form of vitamin D, i.e., 1,25-dihydroxyvitamin D, through the interaction with vitamin D receptor, exerts different activities on the innate and adaptive immune system, among which suppression of inflammation and promotion of tolerogenic responses. Vitamin D insufficiency has been linked to autoimmune disorders that commonly display significant differences between females and males due to genetic, epigenetic, hormonal, and environmental factors. Notably, a number of studies recently showed a cross-talk between vitamin D and the sex hormone estrogen. Estrogen-mediated effects on immune response may favor a Th1 profile or a Th2 profile, depending on hormone concentration. Thus, estrogen-mediated effects appear to be variable on autoimmunity depending on its concentration but also on the pathogenic mechanisms underlying the different autoimmune diseases (i.e., Th1- or Th2-mediated diseases). Notably, estrogen has been demonstrated to enhance vitamin D function favoring its accumulation, and increasing the expression of vitamin D receptor, thus resulting in a more potent anti-inflammatory response in females than males. On the other hand, vitamin D has been shown to downregulate in immune cells the expression of aromatase, which converts testosterone to estrogen, leading to a decrease in estrogen level. Overall, available data allow us to hypothesize a higher protective effect of vitamin D-based therapeutic approaches in women, at least in fertile age, than in men. Future studies are needed to expand current knowledge on the immunomodulatory role of vitamin D in a sex and gender perspective, paving the way to a more personalized therapeutic approach in autoimmune diseases.


Vitamin D is well known for its essential role in regulating calcium homeostasis and maintaining healthy bones [1]. Numerous studies suggest that vitamin D has many other effects, such as the modulation and regulation of innate and adaptive immune responses [2,3,4]. The majority of vitamin D is produced by the human body through the action of sunlight, while smaller amounts are obtained from dietary sources. Gender seems to affect 25-hydroxyvitamin D (25(OH)D) level, that represents the biomarker of vitamin D status, although contrasting results have been reported, some data showing higher 25(OH)D levels in males [5] and others in females [6]. However, some evidence suggests sex-specific determinants in the modulation of 25(OH)D level [7]. For instance, the time spent outdoors seems to have an effect on 25(OH)D mainly in women, whereas physical activity and smoking predict 25(OH)D level in men [7].

Vitamin D deficiency adversely affects bone mass causing rickets in children and adolescents, and osteoporosis and osteomalacia in adults. In addition, vitamin D deficiency has been also linked to the onset/maintenance of other diseases including cardiovascular diseases [8], chronic obstructive pulmonary diseases [9], allergic asthma [10], type 2 diabetes [11], and autoimmune diseases [12,13,14].

The two major types of vitamin D are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). The vitamin D2 is mainly human-made and added to foods, whereas vitamin D3 is synthesized in the skin of humans from 7-dehydrocholesterol although it can also found in animal-based foods (like cod liver oil and oily fish); both forms function as prohormones.

The activation of vitamin D involves two enzymatic hydroxylation reactions. The first is mediated by the 25-hydroxylase (CYP2R1) that converts, in the liver, the vitamin D to 25-hydroxyvitamin D form (25(OH)D) [15]. The second reaction converts 25(OH)D to 1,25-dihydroxyvitamin D (1,25(OH)2D) or calcitriol, the active form, by 1α-hydroxylase (CYP27B1) in kidney or other organs [15]. CYP27B1 is induced by hypocalcemia and hypophosphatemia whereas hypercalcemia and hyperphosphatemia reduce its expression [16]. 1,25(OH)2D binds to vitamin D binding protein to be transported in the blood stream. 1,25(OH)2D is also the active ligand for the vitamin D receptor (VDR) which is present in many tissues and even in different cell types not involved in the regulation of calcium and phosphate metabolism, including immune cells such as dendritic cells (DCs), macrophages/monocytes, neutrophils, T and B lymphocytes. VDR is a transcription factor and member of the steroid hormone nuclear receptor family. After binding with 1,25(OH)2D, VDR heterodimerizes with the retinoid X receptor, forming a complex with high affinity for the vitamin D response element that modulates gene expression in a ligand-dependent manner [17].

Over the last decades, it has been demonstrated that VDR regulates the transcription of numerous genes involved in innate and adaptive immunity, exerting modulatory effects on the immune system [2]. The VDR gene may also present diverse polymorphisms that affect its function and some of these polymorphisms (for example FokI, BsmI, and TaqI) have been shown to predispose to autoimmune diseases, disorders characterized by an exaggerated immune response that leads to organ and tissue damage [18, 19]. Notably, autoimmune disease occurrence has been associated with low circulating levels of 25(OH)D [12]. Most autoimmune diseases are more prevalent in women than in men. Symptom severity, disease course, response to therapy, and overall survival may also differ between males and females with autoimmune diseases [20]. Genetic, epigenetic, sex hormones, and environmental factors are crucial determinants in affecting these differences [21, 22]. Regarding sex hormones (e.g., estrogens and androgens), their effects on autoimmunity appear to be diverse depending on the hormone level, the specific receptor types expressed in immune cells, and the pathogenic mechanism underlying the different autoimmune diseases [23]. For instance, androgens, in particular testosterone, display an anti-inflammatory and immunosuppressive role [24, 25], whereas estrogens display a dual effect depending on their concentration. In fact, high levels of estrogens (e.g., periovulatory or pregnancy levels) promote a shift from a pro-inflammatory T helper 1 (Th1)/Th17 immune response toward an anti-inflammatory Th2/T regulatory (Treg) response whereas low levels of estrogens (e.g., luteal or postmenopausal levels) induce an opposite shift [26, 27]. Thus, menarche, menses, pregnancy, postpartum period, menopause, and the use of hormone replacement therapies all impact disease activity [28]. For instance, pregnancy is associated with an increase in disease flares in the autoimmune disease systemic lupus erythematosus (SLE) due to the increased Th2 response and the enhanced production of pathogenic autoantibodies [29]. Conversely, high levels of estrogens during pregnancy have a protective effect in Th1-dominant autoimmune diseases, like multiple sclerosis (MS) and rheumatoid arthritis (RA) [21, 29].

Notably, growing evidence suggests a cross-talk between sex hormones and vitamin D. While studies on the interaction between androgens and vitamin D are at the beginning [30], the interaction between estrogens and vitamin D has been more widely investigated supporting the synergistic role of these hormones in sex bias of autoimmune diseases.

In this review, we summarize the impact of vitamin D in immunity and autoimmunity, with a special focus on its interaction with estrogens, taking into account the differential estrogen-mediated effects in autoimmune diseases. Three classical female-predominant autoimmune diseases, i.e., MS, RA, and SLE, characterized by different impact of estrogen-mediated effects on disease pathogenesis, will be analyzed in details.

Vitamin D, sex hormones, and immune system

Vitamin D and immune system

The active form of vitamin D, 1,25(OH)2D, exerts immunologic activities on multiple components of the innate and adaptive immune system [2,3,4]. 1,25(OH)2D regulates innate immune cell subsets differentiation and maturation, antigen presentation, and production of cytokines and chemokines. In monocytes/macrophage, besides its direct antibacterial effect on transcription of antimicrobial peptides such as cathelicidin and β-defensin 2 [31], 1,25(OH)2D inhibits inflammation by suppressing the expression of Toll-like receptor (TLR)2/4 and the production of inflammatory cytokines such as interleukin (IL)-1, IL-6, and tumor necrosis factor alpha (TNF-α) that play a crucial pathogenic role in autoimmune diseases [32]. Several studies demonstrated that 1,25(OH)2D negatively regulates the differentiation, maturation and immunostimulatory ability of DCs by reducing the expression of major histocompatibility complex class II (MHC-II), CD40, CD80 and CD86 molecules and the maturation proteins CD1a and CD83 [33, 34]. Notably, in vitamin D receptor knockout (VDR KO) mice, absence of VDR results in increased maturity of lymph node DCs [33]. In addition, 1,25(OH)2D promotes a tolerogenic state decreasing the synthesis of IL-12 and type 1 interferon (IFN) and enhancing that of IL-10 [35]. Together, these effects of 1,25(OH)2D inhibit DC-mediated T cell activation. Regarding T lymphocytes, 1,25(OH)2D inhibits T cell proliferation and IFN-γ and IL-17 production whereas it enhances IL-4 and IL-10 production, favoring a switch from a Th1 and Th17 to a Th2 and Treg cytokine profiles [36]. Additionally, 1,25(OH)2D induces Treg differentiation [37].

Finally, 1,25(OH)2D influences the activation of B cells, the differentiation in plasma cells, and the production of antibodies. In particular, it suppresses the differentiation from mature B cells to plasma cells and class-switched memory B cells, also reducing immunoglobulin production including autoantibodies [38, 39]. As observed for DCs, vitamin D is able to downregulate the expression of the co-stimulatory molecule CD86 in B cells interfering with T cell activation [40]. This control on B cell function is clinically relevant in autoimmune diseases as B-cells producing autoantibodies play a crucial role in the pathophysiology of autoimmunity. The role for low serum 25(OH)D as a risk factor in autoimmunity is reinforced by the observation that healthy subjects, positive for antinuclear antibody (ANA), are significantly more likely to show low vitamin D serum levels than healthy subjects negative for these autoantibodies [41].

Estrogen and immune system

Estrogens, in particular 17-β estradiol (E2), can influence the immune system due to the presence of estrogen receptors on immune cells [42,43,44]. As stated above, estrogen effects depend on hormone concentration but also on the type of target cells and the estrogen receptor subtype expressed on a given cell type [23]. In particular, 17-β estradiol (E2), at high levels (e.g., periovulatory or pregnancy levels) exerts mainly anti-inflammatory actions such as (i) inhibition of the production of pro-inflammatory cytokines, e.g., TNF-α, IL-1β, and IL-6, (ii) induction of the expression of anti-inflammatory cytokines, e.g., IL-4, IL-10, and transforming growth factor (TGF)-β, (iii) promotion of Treg function, and (iv) inhibition of the migration of leukocytes, particularly neutrophils and monocytes, into inflamed areas [27, 45, 46]. At lower concentrations (e.g., luteal or postmenopausal levels), E2 stimulates TNF-α, IFN-γ, and IL-1β production and natural killer (NK) cell activity [27, 45, 46]. Both at high and low concentrations, E2 suppresses bone marrow B cell lineage precursors but enhances antibody production including autoantibodies [27, 45,46,47,48].

Cross-talk between vitamin D and estrogen

Some effects of vitamin D appear to be different in men and women and strictly related to its interplay with estrogens. Interestingly, studies in humans and in animal models showed that E2 is able to decrease the expression of CYP24A1, the cytochrome P450 component of the 25-hydroxyvitamin D(3)-24-hydroxylase enzyme, which inactivates vitamin D [49,50,51]. This effect leads to vitamin D accumulation, thus resulting in a more potent anti-inflammatory response in females than in males. Interestingly, the anti-inflammatory effects mediated by E2 in females could be reproduced treating immune cells from male subjects with this hormone [51]. In addition, E2 increases the expression of VDR gene in diverse human and rat tissues [52,53,54] and, in particular, in CD4+ T cells from mice [50]. The relationship between E2 and vitamin D is further supported by (i) the significant increase of 25(OH)D levels observed in women assuming estrogen containing contraceptives [55], and (ii) the association between low 25(OH)D levels and low E2 levels in women [56].

On the other hand, 1,25(OH)2D affects in a tissue-specific way peripheral estrogen metabolism [57]. In mouse splenic T lymphocytes, 1,25(OH)2D enhances the expression of the CYP19 gene encoding aromatase, the enzyme that produces E2 from testosterone [50]. Vitamin D stimulation of CYP19 gene transcription has also been described in human glial cells [58], placental trophoblasts [59], and osteoblasts [60,61,62]. Conversely, 1,25(OH)2D has been observed to downregulate aromatase expression and inflammatory cytokines in human macrophages by a direct inhibition of its transcription via promoter II and, indirectly, inducing a decrease in the level and function of prostaglandins which are well-known stimulators of aromatase transcription [63, 64]. Figure 1 summarized the cross-talk between vitamin D and estrogen and its impact on immune response.

Fig. 1

Cross-talk between vitamin D and estrogen and vitamin D effects on immune response. Estrogen decreases the expression of CYP24A1, which is involved in the inactivation of vitamin D, and increases the expression of VDR gene. 1,25(OH)2D downregulates aromatase expression, decreasing estrogen level. 1,25(OH)2D also regulates immune cell subsets, interfering with antigen presentation and cytokine production

Multiple sclerosis

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease mediated by organ-specific T cells. Neurological dysfunction is due to the formation of focal lesions in the central nervous system (CNS) resulting in demyelination, loss of oligodendrocytes, and axonal damage [65]. Commonly, MS is characterized by exacerbations and remissions (relapsing-remitting) followed by a secondary progressive course. Less frequently, MS shows a primary progressive course. MS is three times more common in women than in men in most parts of the world, and the onset of the disease occurs earlier in females than in males. The sex ratio in MS appears to be increasing; this trend is observed mainly in relapsing-remitting MS and is linked to a latitudinal gradient suggesting that a complex interaction among genetic and epigenetic factors, sex hormones, and environmental factors takes place [66]. Even though women have a higher risk of developing MS as compared to men, female sex is associated with a better clinical outcome in relapse-remitting MS and a lower accumulation of disability compared to male sex [67]. During pregnancy a decrease of MS activity, followed by a rebound in the first 3 months postpartum, has been observed [68]. This effect is, at least partially, due to the estriol- and progesterone-induced immunological changes favoring a Th2 (anti-inflammatory cytokines) over a Th1 (pro-inflammatory cytokines) profile whereas the opposite happens in the postpartum period. In addition, disease severity seems to worsen after menopause [69]. Overall these epidemiological data suggest a protective role for E2 in MS, also confirmed by in vivo experiments in which this hormone inhibited clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) in mice [70]. Growing evidence suggests that vitamin D is an environmental factor significantly affecting MS prevalence that is closely associated with the latitudinal gradient, where an increased exposure to UVB stimulates the cutaneous production of vitamin D reducing the risk of disease [71, 72]. Accordingly, low levels of 25(OH)D, in association with the presence of genetic polymorphisms involving the metabolism of vitamin D, imply a greater risk of developing MS [73,74,75]. In addition, it has been observed that the presence of gene variants of the CYP27B1 seems to increase the risk and activity of MS [76,77,78].

MS patients have lower serum levels of 25(OH)D than healthy subjects, associated with an increase in self-reactive T lymphocytes in the CNS. No differences have been demonstrated in vitamin D levels between female and male MS patients [51]. However, vitamin D deficiency seems to have a major effect in terms of increasing susceptibility to MS in women than in men [51]. In fact, in vitro treatment of CD4+ T lymphocytes from MS patients with 1,25(OH)2D reduced T cell proliferation as well as IFN-γ and IL-17 production, and increased IL-10 production, with a greater effect in lymphocytes isolated from female than male patients [51]. Notably, T lymphocytes from male MS patients, in the presence of 1,25(OH)2D plus E2, showed a significant decrease in proliferation rate and a significant increase in IL-10 production, similar to those observed in cells isolated from female patients. These data suggest a strict interaction between vitamin D and E2, further supported by studies in animal models of EAE. In this model, the administration of 1,25(OH)2D inhibited the induction of EAE in female mice but not in male mice or ovariectomized (OVX) female mice [79]. E2 was also able to restore vitamin D-mediated EAE protection in female OVX mice [79]. In addition, in EAE-induced female mice, vitamin D reduced demyelination, increased the production of IL-4, IL-10, and TGF-β, and reduced the production of IFN-γ, IL-6, TNF-α, and IL-17, thus favoring a shift from Th1 and Th17 to Th2 and Treg phenotypes [80]. Interestingly, in T lymphocytes from a mouse model of EAE, E2 was able to enhance the expression of Vdr gene and to suppress that of Cyp24a1 gene which is involved in vitamin D degradation, thus prolonging its half-life [50]. Additionally, in this mouse model, E2 displayed a protective role against EAE in wild-type but not in mice lacking Vdr gene in CD4+ T cells, suggesting that E2 action is dependent on Vdr+CD4+ T cells [50]. E2 also increased Treg cells in a Vdr-dependent manner further supporting a synergy between E2 and vitamin D [50]. Overall, the cross-talk between vitamin D and estrogen suggests that therapeutic strategies based on vitamin D could be more effective in females than in males. In addition, deprivation of vitamin D and E2, present in menopausal women, could favor disease progression in this group of MS patients. Up to date, results from clinical studies regarding vitamin D supplementation, alone or in combination with other drugs, in MS patients are controversial [81]; some studies showing a beneficial effect of this hormone in decreasing relapse rate and ameliorating inflammatory markers and magnetic resonance imaging findings [82,83,84,85] whereas other studies showing no benefits on disease outcomes [86,87,88,89,90,91,92]. All the above-mentioned studies are underpowered and large randomized-controlled trials are required to better understand the effect of vitamin D supplementation in MS, stratifying data by sex, age, and stage of the disease. Studies in animal models and in humans on the effects of vitamin D in MS are summarized in Table 1.

Table 1 Studies in animal models and in humans on the effects of vitamin D in MS

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease found in all geographical areas affecting 1–2% of the world population with an apparent reduction in the northern hemisphere [93, 94]. Symptomatology is characterized by the appearance of symmetric arthritis with the predominant involvement of small joints. Due to its systemic nature, the disease can affect other organs and systems with a wide variety of extra articular manifestations (e.g., rheumatoid nodules, vasculitis, and some cardiac dysfunctions) [94]. As observed in most autoimmune diseases, RA shows a higher incidence in females especially in the post-menopausal period (female:male ratio of 3:1). In addition, disease severity seems to be worse in women than in men [95, 96]. Women are more likely to display conditions like depression, fibromyalgia, osteoporosis, and thyroid dysfunctions than males. A key role in the pathogenesis of RA is played by Th1 and Th17 cells, which contribute to maintaining a chronic inflammatory state at the level of the joint synovium [97]. The etiology of RA is still unknown but, also in this instance, the interaction between genetic, epigenetic, hormonal, and environmental factors is believed to be fundamental in the development of the disease [94]. Regarding sex hormones, a multifaceted role in RA onset and severity has been revealed [46, 98]. The female to male ratio of 3:1 may suggest that estrogens increase the risk of RA. However, some data, such as (i) the peak incidence at age 45–55, which coincides with the perimenopausal years, (ii) the lack of association between hormonal therapy and the risk of developing RA, and (iii) the reduction of disease activity during pregnancy, support a systemic anti-inflammatory effect of estrogens. On the other hand, at local level, a pro-inflammatory role for estrogens in peripheral tissues of RA patients has been suggested [99,100,101]. In both male and female RA patients, estrogens are strongly upregulated in synovial fluid due to the increased aromatase activity in monocyte-derived macrophages, induced by local inflammatory cytokines (TNF-α, IL-6, IL-1). The upregulated estrogen concentrations detected in synovial fluid of RA patients are mainly characterized by the hydroxylated forms, in particular 16α-hydroxyestrone which displays a mitogenic activity, supporting the proliferative state of the synovial cells. Interestingly, as stated above, it has been demonstrated that vitamin D is able to decrease the expression of aromatase in human macrophages hampering local inflammation [63].

Thus, a vitamin D deficiency could contribute to synovial inflammation in RA, leading to downregulation of aromatase activity and increased synthesis of estrogens.

More generally, different studies in animal models and in humans support a role for vitamin D in RA development and severity. In animal models of RA, vitamin D was found to reduce the development and the severity of the disease, also being able to reduce anti-type II collagen antibodies (that are associated with inflammation, particularly at RA onset) and to shift the CD4+ differentiation from a Th1-Th17 to a Treg phenotype [102,103,104,105]. Consistent with in vivo studies, in vitro studies carried out in human immune cells suggest a protective role for vitamin D in RA. In monocyte-derived macrophages of RA patients, 1,25(OH)2D was able to reduce the production of pro-inflammatory cytokines (i.e., TNF-α, IL-1α, IL-1β, and IL-6) and receptor activator of nuclear factor κβ ligand (RANKL), a molecule that induces the differentiation and activation of osteoclasts, thus favoring bone resorption [106]. Vitamin D was also able, in combination with the immunosuppressive drug dexamethasone, to induce tolerogenic DCs, characterized by a defective ability of stimulate T cells, thus suppressing T cell proliferation, IFN-γ, and IL-17 production [107].

In line with these observations, patients with RA show basal serum levels of 25(OH)D lower than healthy controls, and a negative correlation between serum 25(OH)D and RA disease activity was revealed by multiple studies [14, 108, 109]. Notably, vitamin D deficiency also appears as an environmental risk factor for RA [14]. Different studies exploring the association between ultraviolet light exposure and RA risk showed a lower RA risk associated with higher UV-B exposure [110, 111]. In the same vein, vitamin D intake was inversely correlated with the risk of developing RA, at least in postmenopausal women [112]. Furthermore, genetic polymorphisms of VDR (e.g., FokI, TaqI), which may affect vitamin D function, seem to represent additional risk factors in the onset of the disease [19].

All the above-mentioned data suggest a role for vitamin D in the prevention and clinical management of RA. However, available studies on the effect of vitamin D supplementation in RA patients show inconsistent results, revealing, on the one hand, a positive effect of vitamin D on disease risk and activity [113,114,115,116] and, on the other hand, no relevant effects on disease outcomes [117]. Studies in animal models and in humans on the effects of vitamin D in RA are summarized in Table 2.

Table 2 Studies in animal models and in humans on the effects of vitamin D in RA

Overall, further studies are needed to clarify the effect of estrogens on vitamin D metabolism and function and to verify whether, as observed in MS, the protective role of estrogens at the systemic level could be mediated, at least partially, by their effect on vitamin D function. Obtained results could allow us to better understand whether therapeutic strategies based on vitamin D could be more effective in females than in males, and whether the decrease of both vitamin D and estrogens, occurred in menopausal women, could favor disease onset and progression.

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease with immunological pathogenesis characterized by the involvement of numerous organs including the kidneys and heart, and tissues, such as the skin, muscle, and joints [118, 119]. The symptomatology is represented by the appearance of fever, joint pain, photosensitivity, pleuropericarditis, convulsions, and nephrotic syndrome. The etiology of SLE still remains not fully elucidated but genetic, environmental, and hormonal factors are likely to be involved in disease onset and progression. Profound functional alterations of lymphocytes have been demonstrated including hyperactivity of T and B cells, abnormal T cell-B cell interaction, dysregulated cytokine, and autoantibody production [120,121,122]. Ninety percent of patients with SLE are females in reproductive age [45]. In addition, women have in general more frequent relapses of disease, whereas men have a late onset of the disease and some more serious comorbidities (e.g., renal comorbidities) [45, 123].

Epidemiological, clinical, and experimental data clearly point to the role of estrogen in the development and clinical manifestations of SLE [21, 124,125,126]. The change in the female to male ratio with age (i.e., prepuberal age F:M = 2:1, fertile age F:M = 9:1, and postmenopausal age F:M = 3:1) is indicative of the estrogen pathogenetic effect. Accordingly, the use of contraceptive or hormone replacement therapy increases the risk of developing SLE [127]. In addition, differently with that observed in MS and RA, an increase of SLE activity, at least in those women with active disease, was observed during pregnancy due to the Th1 to Th2 shift profile leading to an increase of disease flares and autoantibody production [128, 129]. Finally, as in RA, also in SLE patients, the aromatase activity analyzed in the skin and subcutaneous tissues showed a tendency toward an increase when compared with control subjects [98]. The pathogenetic effect of estrogen in SLE is also supported by in vivo studies in lupus mouse models in which ER deficiency attenuates glomerulonephritis and increases survival [130,131,132].

As for other autoimmune diseases, also for SLE a role for vitamin D has been suggested in disease development and activity [133,134,135]. In animal models, a protective effect of vitamin D on disease onset and progression has been observed. In particular, 1,25(OH)2 D3 enhances Treg cells, reduces Th1, Th2, Th17 cells, and autoantibody production, thus ameliorating disease manifestations [136,137,138,139]. In humans, vitamin D deficiency is more common in SLE patients than in healthy individuals [140], possibly caused by different reasons such as the reduced sun exposure due to photosensitivity of SLE patients and the occurrence of renal dysfunction, a typical feature of the disease, with consequent inability to convert vitamin D into its active form [133]. In addition, different polymorphisms of the VDR gene have been associated with higher risk for SLE [18].

Low circulating levels of vitamin D have been associated with SLE disease activity as well as extra-musculoskeletal complications such as fatigue, cardiovascular risk, and cognitive impairment [133,134,135, 141, 142]. A beneficial role of vitamin D in SLE is supported by in vitro studies in peripheral blood mononuclear cells from SLE patients treated with this hormone showing a reduction of anti-DNA antibody production [143] and an inhibition of DC maturation and differentiation [144, 145]. However, the immunomodulatory effects of vitamin D supplementation in SLE patients are still controversial [133,134,135, 142]. In fact, on the one hand, some studies failed to observe any significant change induced by vitamin D supplementation in SLE disease activity and serology [146,147,148,149]. On the other hand, supplementation of vitamin D has been observed to reduce disease activity by an immunosuppressive and anti-inflammatory effect resulting in (i) increase of Treg cells, (ii) decrease of pathogenetic Th1 and Th17 cells, and (iii) decrease of memory B cells and anti-DNA antibodies [113, 150,151,152]. Studies in animal models and in humans on the effects of vitamin D in SLE are summarized in Table 3.

Table 3. Studies in animal models and in humans on the effects of vitamin D in SLE

Interestingly, regarding the cross-talk between vitamin D and estrogen, Kokic and coworkers [153] showed that estrogen, only at low concentration, may have a strong modulating effect on vitamin D function. In fact, studying the potential association between vitamin D and estrogen in SLE, these authors found a significant negative correlation between 25(OH)D and SLE flair in female patients with low serum levels of estrogen. At high values of estrogen, the association between 25(OH)D and SLE flair was not statistically significant, suggesting that vitamin D in this condition lose its protective effect. In this regard, further studies should be carried out to define the molecular mechanism underlying this observation and could open new perspectives in the management of SLE in particular during pregnancy.


Vitamin D has a key role in modulating immune function with important consequences on health maintenance and disease occurrence, particularly autoimmune disorders. Low serum levels of 25(OH)D have been associated with increased risk of autoimmune disease onset and/or high disease activity. In light of this observation, several studies on the usage of vitamin D for treatment or prevention of these diseases have been carried out. However, optimal doses and duration of supplementation are far to be clearly defined because they may vary between patients, also depending on age and sex. In fact, the elderly population is mostly at risk of developing hypovitaminosis D [154] and gender seems to influences 25(OH)D level by gender-specific determinants such as the time spent outdoors for women and smoking for men [7]. Notably, a cross-talk between vitamin D and estrogen has been suggested by in vivo and in vitro studies, supporting higher protective effects for 1,25(OH)2D in females than in males. However, no information is available regarding fluctuation in estrogen level during women’s life (e.g., pre and postmenopausal period) that should be considered as an important variable in this context. The molecular interaction between vitamin D and estrogen has been well elucidated in MS whereas in RA and in SLE further studies are needed to better characterize this relationship, taking into account the impact of these hormones in disease pathogenesis.

Perspectives and significance

Overall, this review highlights the importance to expand current knowledge on the immunomodulatory role of 1,25(OH)2D in a sex and gender perspective. This aspect, from a clinical point of view, is noteworthy because an appropriate sex- and age-specific supplementation of vitamin D could represent a useful tool for the treatment of autoimmune diseases. In fact, although the current treatment for these diseases has improved significantly in recent years, particularly with the use of biologics, it is often not disease-modifying and harmful side effects occur [155].

Future clinical studies are needed to define optimal doses of vitamin D for each patient, and how to achieve and maintain these levels taking into account sex and age. In addition, further studies investigating the efficacy of vitamin D in combination with estrogen agonists, at least in those autoimmune diseases in which estrogen display a protective and anti-inflammatory effect such as MS, could lead to new treatment strategies.

Availability of data and materials

Not applicable.



1,25-Dihydroxyvitamin D


25-Hydroxyvitamin D


Antinuclear antibody


Central nervous system


Cytochrome P450 family 24 subfamily A member 1




Dendritic cells


17-β Estradiol


Experimental autoimmune encephalomyelitis






Major histocompatibility complex class II


Multiple sclerosis


Natural killer




Rheumatoid arthritis


Receptor activator of nuclear factor κβ ligand


Systemic lupus erythematosus


Transforming growth factor beta


T helper


Toll-like receptor


Tumor necrosis factor alpha


T regulatory


Vitamin D receptor


Vitamin D receptor knockout


  1. 1.

    Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, et al. Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev. 2018;40(4):1109–51.

    PubMed Central  Article  PubMed  Google Scholar 

  2. 2.

    Chun RF, Liu PT, Modlin RL, Adams JS, Hewison M. Impact of vitamin D on immune function: lessons learned from genome-wide analysis. Front Physiol. 2014;5:151.

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Charoenngam N, Holick MF. Immunologic effects of vitamin D on human health and disease. Nutrients. 2020;12(7):2097.

  4. 4.

    Toubi E, Shoenfeld Y. The role of vitamin D in regulating immune responses. Isr Med Assoc J. 2010;12(3):174–5.

    PubMed  Google Scholar 

  5. 5.

    McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, et al. Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172(1):21–35.

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Hagenau T, Vest R, Gissel TN, Poulsen CS, Erlandsen M, Mosekilde L, et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20(1):133–40.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Jungert A, Neuhauser-Berthold M. Sex-specific determinants of serum 25-hydroxyvitamin D3 concentrations in an elderly German cohort: a cross-sectional study. Nutr Metab (Lond). 2015;12:2.

    Article  CAS  Google Scholar 

  8. 8.

    Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014;160(6):398–406.

    PubMed  Article  Google Scholar 

  9. 9.

    Black PN, Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest. 2005;128(6):3792–8.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Litonjua AA, Weiss ST. Is vitamin D deficiency to blame for the asthma epidemic? J Allergy Clin Immunol. 2007;120(5):1031–5.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr. 2011;65(9):1005–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Murdaca G, Tonacci A, Negrini S, Greco M, Borro M, Puppo F, et al. Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev. 2019;18(9):102350.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Bellan M, Andreoli L, Mele C, Sainaghi PP, Rigamonti C, Piantoni S, et al. Pathophysiological role and therapeutic implications of vitamin D in autoimmunity: focus on chronic autoimmune diseases. Nutrients. 2020;17:12(3).

    Google Scholar 

  14. 14.

    Harrison SR, Li D, Jeffery LE, Raza K, Hewison M. Vitamin D, autoimmune disease and rheumatoid arthritis. Calcif Tissue Int. 2019;106(1):58–75.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  15. 15.

    Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem. 2003;278(39):38084–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. 16.

    Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010;61:91–104.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, et al. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol. 1999;19(2):1049–55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Zhou TB, Jiang ZP, Lin ZJ, Su N. Association of vitamin D receptor gene polymorphism with the risk of systemic lupus erythematosus. J Recept Signal Transduct Res. 2015;35(1):8–14.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Tizaoui K, Hamzaoui K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology. 2014;220(6):807–16.

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Quintero OL, Amador-Patarroyo MJ, Montoya-Ortiz G, Rojas-Villarraga A, Anaya JM. Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. J Autoimmun. 2012;38(2-3):J109–19.

    CAS  PubMed  Article  Google Scholar 

  21. 21.

    Dupuis ML, Maselli A, Pagano MT, Pierdominici M, Ortona E. Immune response and autoimmune diseases: a matter of sex. Ital J Gender-Specific Med. 2019;5(1):11–20.

    Google Scholar 

  22. 22.

    Rubtsova K, Marrack P, Rubtsov AV. Sexual dimorphism in autoimmunity. J Clin Invest. 2015;125(6):2187–93.

    PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Ortona E, Delunardo F, Maselli A, Pierdominici M, Malorni W. Sex hormones and gender disparity in immunity and autoimmunity. Ital J Gender-Specific Med. 2015;1(2):45–50.

    Google Scholar 

  24. 24.

    Trigunaite A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. Cell Immunol. 2015;294(2):87–94.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front Immunol. 2018;9:794.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  26. 26.

    Cutolo M, Wilder RL. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. Rheum Dis Clin North Am. 2000;26(4):825–39.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–74.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Benagiano M, Bianchi P, D'Elios MM, Brosens I, Benagiano G. Autoimmune diseases: role of steroid hormones. Best Pract Res Clin Obstet Gynaecol. 2019;60:24–34.

    PubMed  Article  Google Scholar 

  29. 29.

    Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J Autoimmun. 2010;34(3):J287–99.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Krysiak R, Kowalcze K, Okopien B. The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia. Clin Exp Pharmacol Physiol. 2020;48(2):186–94.

  31. 31.

    Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182(7):4289–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009;45(3):190–7.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98(12):6800–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol. 2000;164(9):4443–51.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Barragan M, Good M, Kolls JK. Regulation of dendritic cell function by vitamin D. Nutrients. 2015;7(9):8127–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Cantorna MT, Snyder L, Lin YD, Yang L. Vitamin D and 1,25(OH)2D regulation of T cells. Nutrients. 2015;7(4):3011–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Zhou Q, Qin S, Zhang J, Zhon L, Pen Z, Xing T. 1,25(OH)2D3 induces regulatory T cell differentiation by influencing the VDR/PLC-gamma1/TGF-beta1/pathway. Mol Immunol. 2017;91:156–64.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest. 1984;74(2):657–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol. 2007;179(3):1634–47.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  40. 40.

    Drozdenko G, Scheel T, Heine G, Baumgrass R, Worm M. Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clin Exp Immunol. 2014;178(2):364–72.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70(9):1569–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 2015;294(2):63–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Laffont S, Seillet C, Guery JC. Estrogen receptor-dependent regulation of dendritic cell development and function. Front Immunol. 2017;8:108.

    PubMed  PubMed Central  Google Scholar 

  44. 44.

    Pierdominici M, Maselli A, Colasanti T, Giammarioli AM, Delunardo F, Vacirca D, et al. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol Lett. 2010;132(1-2):79–85.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2016;52(2):205–12.

    CAS  PubMed  Google Scholar 

  46. 46.

    Cutolo M, Straub RH. Sex steroids and autoimmune rheumatic diseases: state of the art. Nat Rev Rheumatol. 2020;16(11):628–44.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Medina KL, Kincade PW. Pregnancy-related steroids are potential negative regulators of B lymphopoiesis. Proc Natl Acad Sci U S A. 1994;91(12):5382–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  48. 48.

    Rider V, Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol. 2001;1(6):1009–24.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol. 2005;175(6):4119–26.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Spanier JA, Nashold FE, Mayne CG, Nelson CD, Hayes CE. Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. J Neuroimmunol. 2015;286:48–58.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Correale J, Ysrraelit MC, Gaitan MI. Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects. J Immunol. 2010;185(8):4948–58.

    CAS  PubMed  Article  Google Scholar 

  52. 52.

    Escaleira MT, Sonohara S, Brentani MM. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol. 1993;45(4):257–63.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Liel Y, Shany S, Smirnoff P, Schwartz B. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology. 1999;140(1):280–5.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Schwartz B, Smirnoff P, Shany S, Liel Y. Estrogen controls expression and bioresponse of 1,25-dihydroxyvitamin D receptors in the rat colon. Mol Cell Biochem. 2000;203(1-2):87–93.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Harmon QE, Umbach DM, Baird DD. Use of estrogen-containing contraception is associated with increased concentrations of 25-hydroxy vitamin D. J Clin Endocrinol Metab. 2016;101(9):3370–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  56. 56.

    Zhao D, Ouyang P, de Boer IH, Lutsey PL, Farag YM, Guallar E, et al. Serum vitamin D and sex hormones levels in men and women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas. 2017;96:95–102.

    CAS  PubMed  Article  Google Scholar 

  57. 57.

    Lundqvist J, Norlin M, Wikvall K. 1alpha,25-Dihydroxyvitamin D3 exerts tissue-specific effects on estrogen and androgen metabolism. Biochim Biophys Acta. 2011;1811(4):263–70.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Yague JG, Garcia-Segura LM, Azcoitia I. Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine. 2009;35(2):252–61.

    CAS  PubMed  Article  Google Scholar 

  59. 59.

    Barrera D, Avila E, Hernandez G, Halhali A, Biruete B, Larrea F, et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J Steroid Biochem Mol Biol. 2007;103(3-5):529–32.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Tanaka S, Haji M, Takayanagi R, Sugioka Y, Nawata H. 1,25-Dihydroxyvitamin D3 enhances the enzymatic activity and expression of the messenger ribonucleic acid for aromatase cytochrome P450 synergistically with dexamethasone depending on the vitamin D receptor level in cultured human osteoblasts. Endocrinology. 1996;137(5):1860–9.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Enjuanes A, Garcia-Giralt N, Supervia A, Nogues X, Mellibovsky L, Carbonell J, et al. Regulation of CYP19 gene expression in primary human osteoblasts: effects of vitamin D and other treatments. Eur J Endocrinol. 2003;148(5):519–26.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Yanase T, Suzuki S, Goto K, Nomura M, Okabe T, Takayanagi R, et al. Aromatase in bone: roles of Vitamin D3 and androgens. J Steroid Biochem Mol Biol. 2003;86(3-5):393–7.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Villaggio B, Soldano S, Cutolo M. 1,25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages. Clin Exp Rheumatol. 2012;30(6):934–8.

    PubMed  Google Scholar 

  64. 64.

    Cutolo M. The challenges of using vitamin D in cancer prevention and prognosis. Isr Med Assoc J. 2012;14(10):637–9.

    PubMed  Google Scholar 

  65. 65.

    Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019 Jan;26(1):27–40.

    CAS  PubMed  Article  Google Scholar 

  66. 66.

    Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O. The increasing incidence and prevalence of female multiple sclerosis--a critical analysis of potential environmental factors. Autoimmun Rev. 2011;10(8):495–502.

    PubMed  Article  Google Scholar 

  67. 67.

    Ribbons KA, McElduff P, Boz C, Trojano M, Izquierdo G, Duquette P, et al. Male Sex Is Independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS One. 2015;10(6):e0122686.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  68. 68.

    Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology. 2018;90(10):e840–e6.

    PubMed  Article  Google Scholar 

  69. 69.

    Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, et al. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015;4(1):18–24.

    CAS  PubMed  Article  Google Scholar 

  70. 70.

    Offner H, Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann N Y Acad Sci. 2006;1089:343–72.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Ghareghani M, Reiter RJ, Zibara K, Farhadi N. Latitude, Vitamin D, melatonin, and gut microbiota act in concert to initiate multiple sclerosis: a new mechanistic pathway. Front Immunol. 2018;9:2484.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  72. 72.

    Pierrot-Deseilligny C, Souberbielle JC. Vitamin D and multiple sclerosis: an update. Mult Scler Relat Disord. 2017;14:35–45.

    PubMed  Article  Google Scholar 

  73. 73.

    DeLuca HF, Plum L. UVB radiation, vitamin D and multiple sclerosis. Photochem Photobiol Sci. 2017;16(3):411–5.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Elkama A, Karahalil B. Role of gene polymorphisms in vitamin D metabolism and in multiple sclerosis. Arh Hig Rada Toksikol. 2018;69(1):25–31.

    CAS  PubMed  Article  Google Scholar 

  75. 75.

    Mohammadi A, Azarnezhad A, Khanbabaei H, Izadpanah E, Abdollahzadeh R, Barreto GE, et al. Vitamin D receptor genetic polymorphisms and the risk of multiple sclerosis: A systematic review and meta-analysis. Steroids. 2020;158:108615.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Jiang T, Li L, Wang Y, Zhao C, Yang J, Ma D, et al. The association between genetic polymorphism rs703842 in CYP27B1 and multiple sclerosis: a meta-analysis. Medicine (Baltimore). 2016;95(19):e3612.

    CAS  Article  Google Scholar 

  77. 77.

    Ramagopalan SV, Dyment DA, Cader MZ, Morrison KM, Disanto G, Morahan JM, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol. 2011;70(6):881–6.

    CAS  PubMed  Article  Google Scholar 

  78. 78.

    Torkildsen O, Knappskog PM, Nyland HI, Myhr KM. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol. 2008;65(6):809–11.

    PubMed  Article  Google Scholar 

  79. 79.

    Nashold FE, Spach KM, Spanier JA, Hayes CE. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol. 2009;183(6):3672–81.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Haghmorad D, Yazdanpanah E, Jadid Tavaf M, Zargarani S, Soltanmohammadi A, Mahmoudi MB, et al. Prevention and treatment of experimental autoimmune encephalomyelitis induced mice with 1, 25-dihydroxyvitamin D3. Neurol Res. 2019;41(10):943–57.

    CAS  PubMed  Article  Google Scholar 

  81. 81.

    McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, Broadley SA. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018;265(12):2893–905.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Laursen JH, Sondergaard HB, Sorensen PS, Sellebjerg F, Oturai AB. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Mult Scler Relat Disord. 2016;10:169–73.

    PubMed  Article  Google Scholar 

  83. 83.

    Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565–71.

    PubMed  Article  Google Scholar 

  84. 84.

    Jelinek GA, Marck CH, Weiland TJ, Pereira N, van der Meer DM, Hadgkiss EJ. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. BMC Neurol. 2015;15:132.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  85. 85.

    Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015;14(2):67–73.

    PubMed  PubMed Central  Google Scholar 

  86. 86.

    Kimball SM, Ursell MR, O'Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86(3):645–51.

    CAS  PubMed  Article  Google Scholar 

  87. 87.

    Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77(17):1611–8.

    CAS  PubMed  Article  Google Scholar 

  89. 89.

    Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int. 2012;2012:452541.

    PubMed  PubMed Central  Google Scholar 

  90. 90.

    Hupperts R, Smolders J, Vieth R, Holmoy T, Marhardt K, Schluep M, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a. Neurology. 2019;93(20):e1906–e16.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Camu W, Lehert P, Pierrot-Deseilligny C, Hautecoeur P, Besserve A, Jean Deleglise AS, et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e597.

  92. 92.

    Dorr J, Backer-Koduah P, Wernecke KD, Becker E, Hoffmann F, Faiss J, et al. High-dose vitamin D supplementation in multiple sclerosis - results from the randomized EVIDIMS (efficacy of vitamin D supplementation in multiple sclerosis) trial. Mult Scler J Exp Transl Clin. 2020;6(1):2055217320903474.

    PubMed  PubMed Central  Google Scholar 

  93. 93.

    Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182–8.

    PubMed  Article  Google Scholar 

  94. 94.

    Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–38.

    CAS  Article  PubMed  Google Scholar 

  95. 95.

    Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2009;36(3):508–11.

    PubMed  Article  Google Scholar 

  96. 96.

    Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7.

    PubMed  PubMed Central  Google Scholar 

  97. 97.

    McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

    CAS  PubMed  Article  Google Scholar 

  98. 98.

    Cutolo M, Capellino S, Sulli A, Serioli B, Secchi ME, Villaggio B, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538–47.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    Capellino S, Montagna P, Villaggio B, Soldano S, Straub RH, Cutolo M. Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol. 2008;26(5):903–9.

    CAS  PubMed  Google Scholar 

  100. 100.

    Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus. 2004;13(9):635–8.

    CAS  PubMed  Article  Google Scholar 

  101. 101.

    Cutolo M, Sulli A, Straub RH. Estrogen metabolism and autoimmunity. Autoimmun Rev. 2012;11(6-7):A460–4.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Tsuji M, Fujii K, Nakano T, Nishii Y. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett. 1994;337(3):248–50.

    CAS  PubMed  Article  Google Scholar 

  103. 103.

    Larsson P, Mattsson L, Klareskog L, Johnsson C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol. 1998;114(2):277–83.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  104. 104.

    Moghaddami M, Mayrhofer G, Anderson PH, Morris HA, Van Der Hoek M, Cleland LG. Efficacy and mechanisms of action of vitamin D in experimental polyarthritis. Immunol Cell Biol. 2012;90(2):168–77.

    CAS  PubMed  Article  Google Scholar 

  105. 105.

    Zhou L, Wang J, Li J, Li T, Chen Y, June RR, et al. 1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through miR-124 Mediated Inhibition of IL-6 Signaling. Front Immunol. 2019;10:178.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  106. 106.

    Neve A, Corrado A, Cantatore FP. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med. 2014;14(3):275–83.

    CAS  PubMed  Article  Google Scholar 

  107. 107.

    Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis. 2010;69(11):2042–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  108. 108.

    Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One. 2016;11(1):e0146351.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  109. 109.

    Mateen S, Moin S, Shahzad S, Khan AQ. Level of inflammatory cytokines in rheumatoid arthritis patients: Correlation with 25-hydroxy vitamin D and reactive oxygen species. PLoS One. 2017;12(6):e0178879.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  110. 110.

    Arkema EV, Hart JE, Bertrand KA, Laden F, Grodstein F, Rosner BA, et al. Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses' Health Study. Ann Rheum Dis. 2013;72(4):506–11.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Cutolo M. Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis. Ann Rheum Dis. 2013;72(4):473–5.

    CAS  PubMed  Article  Google Scholar 

  112. 112.

    Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum. 2004;50(1):72–7.

    CAS  PubMed  Article  Google Scholar 

  113. 113.

    Franco AS, Freitas TQ, Bernardo WM, Pereira RMR. Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96(23):e7024.

    CAS  Article  Google Scholar 

  114. 114.

    Song GG, Bae SC, Lee YH. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2012;31(12):1733–9.

    PubMed  Article  Google Scholar 

  115. 115.

    Andjelkovic Z, Vojinovic J, Pejnovic N, Popovic M, Dujic A, Mitrovic D, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol. 1999;17(4):453–6.

    CAS  PubMed  Google Scholar 

  116. 116.

    Buondonno I, Rovera G, Sassi F, Rigoni MM, Lomater C, Parisi S, et al. Vitamin D and immunomodulation in early rheumatoid arthritis: a randomized double-blind placebo-controlled study. PLoS One. 2017;12(6):e0178463.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  117. 117.

    Allan GM, Cranston L, Lindblad A, McCormack J, Kolber MR, Garrison S, et al. Vitamin D: A Narrative Review Examining the Evidence for Ten Beliefs. J Gen Intern Med. 2016;31(7):780–91.

    PubMed  PubMed Central  Article  Google Scholar 

  118. 118.

    Dorner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344–58.

    PubMed  Article  Google Scholar 

  119. 119.

    Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878–88.

    PubMed  Article  Google Scholar 

  120. 120.

    Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med. 2010;16(2):47–57.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Peng SL. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev. 2009;8(3):179–83.

    CAS  PubMed  Article  Google Scholar 

  122. 122.

    Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology (Oxford). 2007;46(10):1525–30.

    CAS  Article  Google Scholar 

  123. 123.

    Lu LJ, Wallace DJ, Ishimori ML, Scofield RH, Weisman MH. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2010;19(2):119–29.

    PubMed  Article  Google Scholar 

  124. 124.

    Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(29):e4272.

    CAS  Article  Google Scholar 

  125. 125.

    Crosslin KL, Wiginton KL. Sex differences in disease severity among patients with systemic lupus erythematosus. Gend Med. 2011;8(6):365–71.

    PubMed  Article  Google Scholar 

  126. 126.

    Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol. 2014;10(12):740–51.

    CAS  PubMed  Article  Google Scholar 

  127. 127.

    Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007;56(4):1251–62.

    PubMed  Article  Google Scholar 

  128. 128.

    Doria A, Iaccarino L, Arienti S, Ghirardello A, Zampieri S, Rampudda ME, et al. Th2 immune deviation induced by pregnancy: the two faces of autoimmune rheumatic diseases. Reprod Toxicol. 2006;22(2):234–41.

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    Marder W. Update on pregnancy complications in systemic lupus erythematosus. Curr Opin Rheumatol. 2019 Nov;31(6):650–8.

    PubMed  Article  Google Scholar 

  130. 130.

    Li J, McMurray RW. Effects of estrogen receptor subtype-selective agonists on autoimmune disease in lupus-prone NZB/NZW F1 mouse model. Clin Immunol. 2007;123(2):219–26.

    CAS  PubMed  Article  Google Scholar 

  131. 131.

    Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA. Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun. 2008;9(2):137–52.

    CAS  PubMed  Article  Google Scholar 

  132. 132.

    Svenson JL, EuDaly J, Ruiz P, Korach KS, Gilkeson GS. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol. 2008;128(2):259–68.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  133. 133.

    Dall'Ara F, Cutolo M, Andreoli L, Tincani A, Paolino S. Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clin Exp Rheumatol. 2017;36(1):153–62.

    PubMed  Google Scholar 

  134. 134.

    Mak A. The impact of vitamin D on the immunopathophysiology, disease activity, and extra-musculoskeletal manifestations of systemic lupuserythematosus. Int J Mol Sci. 2018;19(8):2355.

  135. 135.

    Shoenfeld Y, Giacomelli R, Azrielant S, Berardicurti O, Reynolds JA, Bruce IN. Vitamin D and systemic lupus erythematosus - The hype and the hope. Autoimmun Rev. 2018;17(1):19–23.

    CAS  PubMed  Article  Google Scholar 

  136. 136.

    Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992;12(2):143–8.

    CAS  PubMed  Article  Google Scholar 

  137. 137.

    Liu D, Fang YX, Wu X, Tan W, Zhou W, Zhang Y, et al. 1,25-(OH)2D3/Vitamin D receptor alleviates systemic lupus erythematosus by downregulating Skp2 and upregulating p27. Cell Commun Signal. 2019;17(1):163.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  138. 138.

    Correa Freitas E, Evelyn Karnopp T, de Souza Silva JM. Cavalheiro do Espirito Santo R, da Rosa TH, de Oliveira MS, et al. Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. Autoimmunity. 2019;52(2):69–77.

    PubMed  Article  CAS  Google Scholar 

  139. 139.

    Yan L, Wu P, Gao DM, Hu J, Wang Q, Chen NF, et al. The impact of vitamin D on cognitive dysfunction in mice with systemic lupus erythematosus. Med Sci Monit. 2019;25:4716–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Islam MA, Khandker SS, Alam SS, Kotyla P, Hassan R. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. Autoimmun Rev. 2019;18(11):102392.

    CAS  PubMed  Article  Google Scholar 

  141. 141.

    Tay SH, Ho CS, Ho RC, Mak A. 25-Hydroxyvitamin D3 deficiency independently predicts cognitive impairment in patients with systemic lupus erythematosus. PLoS One. 2015;10(12):e0144149.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  142. 142.

    Watad A, Neumann SG, Soriano A, Amital H, Shoenfeld Y. Vitamin D and systemic lupus erythematosus: myth or reality? Isr Med Assoc J. 2016;18(3-4):177–82.

    PubMed  Google Scholar 

  143. 143.

    Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol. 2001;99(1):82–93.

    CAS  PubMed  Article  Google Scholar 

  144. 144.

    Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, Marinescu LM, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. PLoS One. 2010;5(2):e9193.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  145. 145.

    Lerman M, Burnham J, Behrens E. 1,25 dihydroxyvitamin D3 limits monocyte maturation in lupus sera. Lupus. 2011 Jun;20(7):749–53.

    CAS  PubMed  Article  Google Scholar 

  146. 146.

    Andreoli L, Dall'Ara F, Piantoni S, Zanola A, Piva N, Cutolo M, et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. Lupus. 2015;24(4-5):499–506.

    CAS  PubMed  Article  Google Scholar 

  147. 147.

    Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, et al. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015;67(7):1848–57.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  148. 148.

    Karimzadeh H, Shirzadi M, Karimifar M. The effect of Vitamin D supplementation in disease activity of systemic lupus erythematosus patients with Vitamin D deficiency: a randomized clinical trial. J Res Med Sci. 2017;22:4.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  149. 149.

    Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken). 2010;62(8):1160–5.

    CAS  Article  Google Scholar 

  150. 150.

    Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther. 2012;14(5):R221.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  151. 151.

    Lima GL, Paupitz J, Aikawa NE, Takayama L, Bonfa E, Pereira RM. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken). 2016;68(1):91–8.

    CAS  Article  Google Scholar 

  152. 152.

    Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013;65(7):1865–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  153. 153.

    Kokic V, Martinovic Kaliterna D, Radic M, Tandara L, Perkovic D. Association between vitamin D, oestradiol and interferon-gamma in female patients with inactive systemic lupus erythematosus: a cross-sectional study. J Int Med Res. 2018;46(3):1162–71.

    CAS  PubMed  Article  Google Scholar 

  154. 154.

    Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem. 2007;18(12):771–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  155. 155.

    Fugger L, Jensen LT, Rossjohn J. Challenges, progress, and prospects of developing therapies to treat autoimmune diseases. Cell. 2020;181(1):63–80.

    CAS  PubMed  Article  Google Scholar 

Download references


Not applicable.

Author information




Writing–original draft preparation, M.L.D and M.T.P.; review and editing, M.P; supervision E.O. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Marina Pierdominici.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dupuis, M.L., Pagano, M.T., Pierdominici, M. et al. The role of vitamin D in autoimmune diseases: could sex make the difference?. Biol Sex Differ 12, 12 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Vitamin D
  • Autoimmunity
  • Multiple sclerosis
  • Rheumatoid arthritis
  • Systemic lupus erythematosus
  • Sex hormones
  • Estrogen
  • Gender
  • Sex